HC Wainwright Reaffirms Buy Rating for Autolus Therapeutics (AUTL)

HC Wainwright reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note released on Friday morning. They currently have a $45.00 target price on the stock.

“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.45, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2027.”,” HC Wainwright’s analyst commented.

Other equities analysts have also issued reports about the company. Goldman Sachs Group assumed coverage on Autolus Therapeutics in a research note on Thursday, July 26th. They set a neutral rating on the stock. Wells Fargo & Co assumed coverage on Autolus Therapeutics in a research note on Tuesday, July 17th. They set an outperform rating and a $38.00 price target on the stock. William Blair assumed coverage on Autolus Therapeutics in a research note on Tuesday, July 17th. They set an outperform rating on the stock. Finally, Jefferies Financial Group assumed coverage on Autolus Therapeutics in a research note on Tuesday, July 17th. They set a buy rating and a $37.00 price target on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Autolus Therapeutics presently has an average rating of Buy and an average target price of $40.00.

Shares of AUTL opened at $31.75 on Friday. Autolus Therapeutics has a 12-month low of $19.17 and a 12-month high of $34.22.

Institutional investors and hedge funds have recently modified their holdings of the stock. Jennison Associates LLC bought a new position in Autolus Therapeutics during the second quarter valued at about $3,168,000. Janus Henderson Group PLC bought a new position in Autolus Therapeutics during the second quarter valued at about $498,000. Hermes Investment Management Ltd. bought a new position in Autolus Therapeutics during the second quarter valued at about $1,248,000. Aquilo Capital Management LLC acquired a new stake in Autolus Therapeutics during the second quarter valued at approximately $4,018,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Autolus Therapeutics during the second quarter valued at approximately $1,011,000. Hedge funds and other institutional investors own 21.17% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Recommended Story: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply